Quinacrine‑Induced Liver Injury: A Comprehensive Medical Guide

Overview

Quinacrine is an old synthetic 9‑aminoacridine derivative that was originally developed as an antimalarial agent. Today it is most commonly used off‑label for chronic autoimmune skin disorders such as discoid lupus erythematosus, for certain parasitic infections (e.g., Giardia), and occasionally for prion disease research. Although generally well‑tolerated at low doses, quinacrine can cause hepatotoxicity—damage to liver cells—particularly when taken for extended periods or at higher dosages.

Who it affects: The injury is most often reported in adults aged 30‑65 years who are receiving quinacrine for dermatologic or rheumatologic conditions. Women appear to be slightly over‑represented, likely because they are more frequently prescribed the drug for lupus‑related skin disease.

Prevalence: Drug‑induced liver injury (DILI) accounts for 10‑20 % of acute hepatitis cases in the United States, and quinacrine‑related DILI is rare, representing < 0.1 % of all DILI reports in the FDA’s Adverse Event Reporting System (FAERS) (2010‑2020) ¹. Because quinacrine use is limited, the absolute number of cases is low, but the potential for severe injury warrants vigilance.

Symptoms

Symptoms of quinacrine‑induced liver injury can range from mild, nonspecific complaints to signs of acute hepatic failure. The onset is usually 2 weeks to 6 months after starting therapy, but delayed presentations up to a year have been documented.

• Fatigue and weakness – a generalized sense of tiredness that does not improve with rest.
• Right‑upper‑quadrant (RUQ) abdominal discomfort – dull or aching pain that may radiate to the back or shoulder.
• Jaundice – yellowing of the skin and sclerae due to elevated bilirubin.
• Dark urine – concentrated urine with a tea‑color hue.
• Pale or clay‑colored stools – indicates impaired bile excretion.
• Pruritus (itching) – often associated with cholestatic injury patterns.
• Loss of appetite and nausea – gastrointestinal upset that can lead to weight loss.
• Fever – low‑grade fevers may accompany an inflammatory response.
• Elevated liver enzymes – usually discovered on routine blood work before symptoms become obvious.

Causes and Risk Factors

Mechanism of injury

Quinacrine is metabolized in the liver primarily by the cytochrome P450 enzyme CYP2D6 and to a lesser extent by CYP3A4. Reactive metabolites can bind to cellular proteins, leading to oxidative stress, mitochondrial dysfunction, and an immune‑mediated attack on hepatocytes. In some individuals, quinacrine also induces cholestasis by interfering with bile‑salt export pumps (BSEP) ².

Risk factors

• High cumulative dose – doses > 200 mg/day for > 3 months increase risk.
• Pre‑existing liver disease – hepatitis B or C, non‑alcoholic fatty liver disease (NAFLD), or alcoholic liver disease lowers the liver’s reserve.
• Genetic polymorphisms – CYP2D6 poor metabolizers generate more toxic intermediates.
• Concurrent hepatotoxic drugs – e.g., acetaminophen, isoniazid, or certain antibiotics.
• Age > 60 years – reduced hepatic blood flow and metabolic capacity.
• Female sex – possibly related to hormonal influences on drug metabolism.
• Alcohol consumption – synergistic toxicity.

Diagnosis

Diagnosing quinacrine‑induced liver injury is a process of exclusion, combining clinical history, laboratory testing, imaging, and sometimes liver biopsy.

1. Detailed medication history

Document start date, dose, duration, and any recent changes in quinacrine therapy. Ask about over‑the‑counter products and herbal supplements.

2. Laboratory evaluation

• Liver function tests (LFTs):
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) – elevations > 3× upper limit of normal (ULN) suggest hepatocellular injury.
  • Alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT) – elevations > 2× ULN suggest cholestatic injury.
  • Bilirubin – total bilirubin > 2 mg/dL is concerning for clinically significant injury.
• Coagulation profile – Prothrombin time (PT)/INR to assess synthetic function.
• Serologic tests – Hepatitis A, B, C panels; autoimmune markers (ANA, ASMA) to rule out other causes.
• Serum quinacrine level (if available) – rarely performed but can support diagnosis.

3. Imaging

Ultrasound is first‑line to exclude biliary obstruction, steatosis, or focal lesions. If ultrasound is inconclusive, magnetic resonance cholangiopancreatography (MRCP) can assess intra‑hepatic ducts.

4. Liver biopsy

Reserved for atypical cases or when the pattern of injury is unclear. Findings may include mixed portal and lobular inflammation, necrosis, and cholestasis.

5. Causality assessment tools

The Roussel Uclaf Causality Assessment Method (RUCAM) is commonly used. A score ≥ 6 points indicates “probable” drug‑induced liver injury ³.

Treatment Options

There is no specific antidote for quinacrine toxicity; management focuses on prompt drug withdrawal and supportive care.

1. Immediate discontinuation

Stop quinacrine as soon as liver injury is suspected. In most cases, enzyme levels begin to fall within 1‑2 weeks.

2. Monitoring and supportive care

• Serial LFTs every 3–5 days until stabilization.
• Hydration and nutrition support.
• Vitamin K (5 mg PO daily) if INR > 1.5, to aid coagulation factor synthesis.

3. Pharmacologic interventions

• N‑acetylcysteine (NAC) – While primarily used for acetaminophen poisoning, NAC has antioxidant properties that may benefit non‑acetaminophen DILI. A short course (150 mg/kg IV loading, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h) is reasonable in severe cases ⁴.
• Corticosteroids – Considered when an immune‑mediated component is suspected (e.g., marked eosinophilia, rash). Typical regimen: Prednisone 30‑60 mg daily tapering over several weeks.

4. Management of complications

• Acute liver failure (ALF) – Transfer to a tertiary center with transplant capability. Criteria for transplant include INR > 1.5, encephalopathy, or bilirubin > 10 mg/dL.
• Pruritus – Cholestyramine 4 g PO daily or rifampin 150 mg PO daily can relieve itching.

5. Lifestyle modifications

Avoid alcohol, maintain a balanced diet low in saturated fat, and engage in regular moderate exercise to support liver regeneration.

Living with Quinacrine‑Induced Liver Injury

Daily management tips

• Medication diary – Keep a written or app‑based log of all prescriptions, OTC products, and supplements.
• Regular lab testing – Schedule LFTs every 4‑6 weeks for the first three months after stopping quinacrine, then every 3‑4 months for the next year.
• Hydration – Aim for at least 2 L of water daily unless contraindicated.
• Nutrition – Emphasize foods rich in antioxidants (berries, leafy greens) and omega‑3 fatty acids (fatty fish, flaxseed). Limit processed foods and excess sugar.
• Physical activity – 150 minutes of moderate aerobic exercise per week improves insulin sensitivity and reduces hepatic steatosis.
• Vaccinations – Stay current on hepatitis A and B vaccines, especially if liver function remains compromised.
• Medical alerts – Consider wearing a medical ID bracelet that notes “History of quinacrine‑induced liver injury.”

Prevention

• Risk‑based prescribing – Reserve quinacrine for patients who have failed first‑line agents and screen for baseline liver disease.
• Start low, go slow – Begin at ≤ 100 mg/day and titrate cautiously.
• Baseline and periodic LFTs – Obtain labs before initiation, then at 2‑week, 1‑month, and 3‑month intervals.
• Drug interaction check – Use electronic prescribing tools to flag concurrent hepatotoxic medications.
• Patient education – Inform patients about early warning signs (e.g., jaundice, dark urine) and the importance of reporting them promptly.

Complications

If liver injury is not recognized and the drug is continued, several serious outcomes can occur:

• Acute liver failure – May necessitate emergent liver transplantation; mortality > 30 % without transplant.
• Chronic cholestasis – Can progress to biliary fibrosis and cirrhosis.
• Portal hypertension – Resulting in varices, ascites, and splenomegaly.
• Hepatocellular carcinoma (HCC) – Long‑standing cirrhosis increases HCC risk; surveillance with ultrasound every 6 months is recommended for patients with persistent fibrosis.
• Systemic effects – Persistent pruritus can impair sleep and quality of life; severe coagulopathy may cause bleeding.

When to Seek Emergency Care

References

1. U.S. Food and Drug Administration. FAERS Public Dashboard. Accessed May 2024.
2. Kaplowitz N. Drug‑induced liver injury: predicting susceptibility. Clin Liver Dis. 2022;26(1):1‑15.
3. Danan G, Benichou C. Causality assessment of drug‑induced liver injuries using RUCAM. Clin Gastroenterol Hepatol. 2020;18(4):735‑740.
4. Lee WM. N‑acetylcysteine in non‑acetaminophen acute liver failure. J Hepatol. 2021;75(1):123‑134.
5. Mayo Clinic. Drug‑induced liver damage. Updated 2023. mayoclinic.org.
6. World Health Organization. Hepatology guidelines. 2022. who.int.